Clinical Trial

Zanubrutinib, Obinutuzumab Combined With Lenalidomide (ZGR) for the Treatment of Untreated Follicular Lymphoma

Study acronym: ZGR in TN FL
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is planned to prospectively evaluates the efficacy and safety of the zanubrutinib, obinutuzumab, and lenalidomide (ZGR) combination regimen in treatment-naïve follicular lymphoma (FL) patients in a Chinese population.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-12-09.
Status change: Not Yet Recruiting → Recruiting 2026-05-10
Trial Details
NCT Number NCT07299149
Lead Sponsor Institute of Hematology & Blood Diseases Hospital, China
Conditions Follicular Lymphoma
Enrollment 34 participants
Start Date 2025-12-25
Primary Completion 2028-04-28 (estimated)
Study Completion 2030-12-25 (estimated)
Updated on ClinicalTrials.gov 2026-05-13